Recent developments in the field include an evolving treatment landscape and the development of evidence-based guidelines.
AbbVie (NYSE:ABBV) has managed to keep its market share for its bestselling arthritis therapy, Humira, above 70%, generic drugmaker Samsung Bioepis said in a new report on Thursday as the ...
Gifting allows recipients to access the article for free. AbbVie leaders are “disappointed” with poor results from a schizophrenia drug the company acquired last year that led to a $3.5 ...
AbbVie (NYSE:ABBV) is facing turbulence after its experimental schizophrenia drug, emraclidine, flopped in two mid-stage trials. The drug, picked up in AbbVie's $8.7 billion acquisition of Cerevel ...
AbbVie has a 12 month low of $153.58 and a 12 month high of $207.32. The company has a debt-to-equity ratio of 9.64, a current ratio of 0.65 and a quick ratio of 0.54.
AbbVie, with a market cap of over $300 billion, shows strong cash flow potential despite patent expirations, making it a valuable investment. The company reported strong 3Q financials, with ...
AbbVie on Friday said it will post a $3.5 billion impairment charge related to last year’s $8.7 billion bet on Cerevel Therapeutics following the failure of the deal’s key drug candidate ...
The failure of Cerevel's emraclidine in schizophrenia will cost AbbVie an impairment charge of about $3.5 billion, the pharma said in a Jan. 10 filing with the Securities and Exchange Commission.
Jan 10 (Reuters) - Abbvie (ABBV.N), opens new tab said on Friday it would record a charge of about $3.5 billion related to its experimental schizophrenia drug, emraclidine, which recently failed ...
AbbVie ABBV underwent analysis by 17 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The table below provides a concise overview of recent ratings by ...
Gene therapy firm Capsida Biotherapeutics is advancing the first of its AbbVie-partnered neurodegenerative disease therapies after the Big Pharma exercised a $40 million option for the program.